Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

• DOI: 10.1016/j.jhep.2004.11.016
• Publication Date: 2004-12-16T05:31:45Z
• Authors: Minoru Nakamura; Yuki Shimizu-Yoshida; Yasushi Takii; Atsumasa Komori; Terufumi Yokoyama; Toshihito Ueki; Manabu Daikoku; Koji Yano; Takehiro Matsumoto; Kiyoshi Migita; Hiroshi Yatsuhashi; Masahiro Ito; Naohiko Masaki; Hiroshi Adachi; Yukio Watanabe; Yoko Nakamura; Takeo Saoshiro; Takeshi Sodeyama; Michiaki Koga; Shinji Shimoda; Hiromi Ishibashi
• Keywords: Male; 0303 health sciences; Membrane Glycoproteins; Liver Cirrhosis, Biliary; Ursodeoxycholic Acid; Nuclear Proteins; Enzyme-Linked Immunosorbent Assay; Middle Aged; Survival Analysis; Antibodies; Disease-Free Survival; Peptide Fragments; Liver Transplantation; 3. Good health; Nuclear Pore Complex Proteins; 03 medical and health sciences; Treatment Outcome; Liver Function Tests; Humans; Female; Biomarkers; Probability; Retrospective Studies

The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved.We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC.Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan.The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.